Wireless ECG patch enters clinical trial in Australia

November 20, 2026
Wireless ECG patch enters clinical trial in Australia
Monitoring
News

A lightweight, wireless ECG patch developed from research at Australia's RMIT University is entering clinical testing in Perth. The wearable device is designed to monitor heart rhythms continuously for up to 14 days without the gels and wires used in conventional Holter monitoring. Earlier tests involving healthy volunteers produced promising results, but the new trial must establish whether the technology can deliver reliable clinical measurements in patients. The development is part of a broader effort to make cardiac monitoring more accessible outside hospitals.

The technology was originally developed at RMIT University and is now being commercialised by Australian start-up Lubdub. Patients prescribed conventional Holter monitoring at Midlands Medical Specialists in Perth will also wear the experimental ECG patch during the trial. The researchers aim to develop a monitoring system that can collect detailed cardiac information while patients continue their normal daily activities. This could be particularly relevant for detecting intermittent heart rhythm abnormalities that may not occur during a short clinical examination.

From laboratory to clinical trial

Unlike conventional Holter monitors, which typically use adhesive electrodes connected to a recording device, the new patch incorporates flexible sensors into a compact, waterproof and wireless design. According to RMIT professor and Lubdub co-founder Sharath Sriram, the flexible sensors provide better contact with the skin than those used in traditional Holter monitoring.

In preliminary testing involving healthy volunteers, the researchers reported that the patch collected signals that were 18 times cleaner than those obtained using conventional Holter monitors. The developers believe improved signal quality could reduce the work required to process cardiac recordings and prepare reports. They estimate that this might eventually allow existing clinical teams to monitor up to 85 percent more patients, even without additional AI tools.

However, these figures are based on the developers' assessment rather than demonstrated improvements in routine clinical practice. The Perth trial will provide further evidence about the patch's performance in patients undergoing cardiac monitoring. The findings are also intended to support continued development and potential regulatory approval.

Expanding wearable heart monitoring

The RMIT development follows several other research projects exploring alternatives to conventional cardiac monitoring equipment. Earlier this year, researchers at Carnegie Mellon University demonstrated that ordinary earbuds could be repurposed to detect subtle vibrations associated with heartbeats and heart valve movements. In a feasibility study involving 18 participants, measurements obtained through earbuds showed strong correlations with conventional chest sensors, ranging from 0.88 to 0.95. Machine learning was used to interpret the recorded signals.

Another Australian research team, at the University of New South Wales, developed the AusculPatch, an ultralight wearable sensor capable of recording mechanical vibrations from the heart, lungs and blood vessels. Weighing just 3.2 grams, the flexible patch can be attached to the chest or positioned over a peripheral artery. Initial experiments showed that it could collect physiological signals during everyday activities, including walking and climbing stairs. Larger clinical studies are planned.

Although these technologies share the objective of extending monitoring beyond clinical settings, they measure different aspects of cardiovascular function. The RMIT patch records electrical activity through ECG measurements, while the Carnegie Mellon and UNSW devices focus on mechanical signals associated with cardiac activity. Consequently, their results cannot be directly compared, and each technology requires clinical validation appropriate to its intended application.

Integrated diagnostics

Lubdub's ambitions extend beyond continuous ECG monitoring. The company intends to combine three technologies within a single software platform: wearable ECG monitoring, non-invasive cardiac biomarker testing and wearable ultrasound imaging. The objective is to bring together diagnostic information that currently often requires separate examinations, appointments and specialist facilities. Such an approach could potentially be useful in regional and remote communities, where access to specialist cardiovascular services may be limited.

However, the proposed integrated platform remains under development. Its clinical effectiveness, practical feasibility and potential benefits for patients have not yet been established. RMIT has licensed intellectual property relating to its ECG and biomarker technologies to Lubdub. The university will continue supporting development through research collaborations and access to pilot manufacturing facilities. The company also announced a $6 million seed funding round in September, exceeding its original $3 million target. Lubdub was selected by the Australian Heart Foundation as one of ten promising heart health projects for 2026.

Clinical evidence

The transition from laboratory testing to clinical evaluation represents an important stage in developing wearable medical technology. For cardiac monitoring, signal quality is only one consideration. Devices must also demonstrate reliable performance during prolonged use, across different patient populations and under everyday conditions.

The ability to collect continuous physiological data does not, by itself, establish that a device improves diagnosis, treatment decisions or patient outcomes. The Perth trial will therefore be an important test of whether the RMIT technology can progress from promising experimental measurements towards a clinically useful alternative to conventional Holter monitoring.

References

RMIT University

Add ICT&health on Google

Show more content from ICT&health in Google Search.

Add on Google

This topic will also have a prominent place at the ICT&health World Conference 2027. Want to be there and stay ahead of what’s next in healthcare? Reserve your ticket today.